Harvard University

Researchers developed patient-specific esophageal adenocarcinoma organ chips that accurately predicted chemotherapy responses in all eight patients tested, overcoming limitations of traditional organoid models.

XtalPi has signed a Letter of Intent with DoveTree LLC, founded by Harvard Professor Gregory Verdine, for a collaboration worth $100 million upfront plus potential milestone payments exceeding $10 billion.

Catalyst Pharmaceuticals appointed Dr. William T. Andrews as Chief Medical Officer, succeeding retiring Dr. Gary Ingenito after his successful 10-year tenure with the company.

Brooklyn Health secured $6.5 million in seed funding led by HealthX Ventures to advance its AI-powered clinical trial measurement technology for central nervous system disorders.

The U.S. Court of Appeals for the Federal Circuit has partially vacated the Patent Trial and Appeal Board's previous decision in the CRISPR/Cas9 patent interference case, remanding it for further review.

The Trump administration issued an unexpected "stop work order" for SMART IRB, a critical system that streamlines multisite clinical trials, leaving researchers across the country baffled.

Vizgen has reached a settlement agreement with 10x Genomics and Harvard University, ending litigation in both U.S. and European courts after three days of trial in Delaware.

Artis BioSolutions has emerged from stealth mode with the strategic acquisition of Landmark Bio, positioning itself as a premier CDMO for advanced genetic medicine development.

Kineticos Life Sciences launches Kinvard Bio to develop novel oxepanoprolinamide antibiotics, licensed from Harvard University's Myers Lab, targeting multi-drug resistant bacterial infections.

Apple has introduced its Research app in the US, enabling iPhone and Watch users to participate in studies on women's health, cardiovascular conditions, and hearing impacts, with leading research institutions.